Dr Sean Leng and the Johns Hopkins-SunInflam team land a $1 million XPRIZE Healthspan Milestone 2 award for aging research.
Part of a ten-part series profiling each of the $101 million XPRIZE Healthspan competition’s Milestone 2 Awardees. Across the series, Longevity.Technology examines the science behind each team’s approach, the trial data supporting it and what stands between them and the competition’s final phase.
Dr Sean Leng has spent close to four decades moving between labs, clinics and continents, and most of that time has circled back to one question: why does the immune system get worse at its job as we age, and can that be reversed? That question earned his team real money to keep chasing an answer.
Leng and the Johns Hopkins-SunInflam team have been named XPRIZE Healthspan Milestone 2 awardees, taking home $1 million along with something arguably more valuable for a research team: guaranteed access to clinical testing infrastructure built specifically for aging science.
A prize built to filter the noise from the promise
XPRIZE Healthspan isn’t a typical grant competition. Launched in 2023 with a $101 million purse spread across a seven-year run, it drew almost 200 applicants worldwide, all claiming they could help people live not just longer, but with more usable years attached.
Every team, whatever their approach, had to clear the same bar: early human evidence that their work could move the needle on muscle function, brain function or immune function, judged against standard metrics set by the prize’s own expert committees. The top 10 projects were announced on 11 August, a mix of Japanese, Korean, Chinese and US groups working on everything from exosomes to supplements to repurposed drugs.
The Johns Hopkins-SunInflam project is one of six US teams that made that cut, and its foundation is Leng’s own research into what scientists call “inflammaging,” the low-grade, chronic inflammation that seems to accumulate quietly in older adults and appears to drive frailty, cognitive decline and a weakened response to infection. Milestone 2 funding doesn’t just recognize the idea; it buys the team room to actually test it in people, using clinical resources the prize provides.
The long road that got him here
Leng’s path to this point started far from Baltimore. Born in China, he trained at Jiangxi Medical College and Peking Union Medical College Hospital before emigrating to the United States in 1989, where he earned a PhD in medical microbiology and immunology at Texas A&M. From there it was a research fellowship in immunology and cytokine biology at Yale, an internal medicine residency in New York, and finally a fellowship in geriatric medicine at Johns Hopkins, where he’s stayed as full-time faculty since 2002.
Today, he’s a professor of medicine, molecular microbiology and immunology, and health policy and management, with joint appointments spanning Johns Hopkins’ medical school and its Bloomberg School of Public Health.
In 2007, Leng was named a Beeson Scholar, one of aging research’s more selective early-career honors, and he’s built out a research program since then focused on frailty, chronic inflammation, influenza immunization and chronic cytomegalovirus infection in older adults, work reflected in more than 200 peer-reviewed papers and book chapters.
He’s also become something of an institution-builder. As president of the Milstein Medical Asian American Partnership Foundation since 2014, and through more than two decades helping establish an academic geriatrics program at Peking Union Medical College Hospital, Leng has spent as much energy connecting researchers across borders as he has running his own experiments.
Beyond one team’s funding
It’s easy to read a $1 million award as a nice headline for one university lab. The more interesting story is what it says about where the field is heading. XPRIZE Healthspan was designed to force a certain kind of rigor onto a longevity industry that’s often accused of running ahead of its evidence, supplements and biohacking claims outpacing anything resembling a controlled trial.
A team built around decades of peer-reviewed inflammation research, rather than a splashy new compound, making it through that filter is a reminder that some of the most promising longevity science isn’t new at all. It’s been quietly accumulating in geriatrics departments for years, waiting for funding and infrastructure to catch up.
For Leng, the SunInflam project is a chance to take research on immune aging out of the mouse model and cell-culture stage and into something closer to a real intervention, tested against the same muscle, brain and immune benchmarks every other finalist has to meet. Whether that translates into a therapy people can actually use is still an open question. But it’s now a better-funded one, with real clinical testing muscle behind it.
